These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17632224)

  • 1. Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia.
    Liu-Seifert H; Houston JP; Adams DH; Kinon BJ
    J Clin Psychopharmacol; 2007 Aug; 27(4):392-4. PubMed ID: 17632224
    [No Abstract]   [Full Text] [Related]  

  • 2. Benzodiazepines in schizophrenia.
    Stimmel GL
    Pharmacotherapy; 1996; 16(6 Pt 2):148S-151S; discussion 166S-168S. PubMed ID: 8947998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.
    Kinon BJ; Hill AL; Liu H; Kollack-Walker S
    Int J Neuropsychopharmacol; 2003 Jun; 6(2):97-102. PubMed ID: 12890301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: treatment noncompliance with orally disintegrating olanzapine tablets.
    Citrome L
    Can J Psychiatry; 2004 Jun; 49(6):412-3; author reply 413. PubMed ID: 15283540
    [No Abstract]   [Full Text] [Related]  

  • 6. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.
    Smelson DA; Tunis SL; Nyhuis AW; Faries DE; Kinon BJ; Ascher-Svanum H
    J Clin Psychopharmacol; 2006 Dec; 26(6):666-7. PubMed ID: 17110828
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode.
    Peuskens J; Kaufman L; Van Vleymen B
    Schizophr Res; 2007 Sep; 95(1-3):169-73. PubMed ID: 17630255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug abuse experience and neuroleptic prescriptions at the onset of schizophrenia].
    Lisoprawski A
    Sem Hop; 1983 Jun; 59(25):1925-7. PubMed ID: 6136096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders.
    Duncan JC; Rogers R
    J Forensic Sci; 1998 Nov; 43(6):1133-7. PubMed ID: 9846389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia.
    Kamali M; Kelly L; Gervin M; Browne S; Larkin C; O'Callaghan E
    Psychiatr Serv; 2001 Feb; 52(2):161-3, 166. PubMed ID: 11157110
    [No Abstract]   [Full Text] [Related]  

  • 11. Positive findings for negative symptoms of schizophrenia: no longer untreatable?
    Stahl SM
    Acta Psychiatr Scand; 2006 Nov; 114(5):301-2. PubMed ID: 17022789
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine and haloperidol for residual symptoms.
    de Haan L; van Beveren N
    Am J Psychiatry; 2005 Jul; 162(7):1392-3; author reply 1393. PubMed ID: 15994737
    [No Abstract]   [Full Text] [Related]  

  • 15. Medication noncompliance and substance abuse among patients with schizophrenia.
    Owen RR; Fischer EP; Booth BM; Cuffel BJ
    Psychiatr Serv; 1996 Aug; 47(8):853-8. PubMed ID: 8837158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication compliance and substance abuse among schizophrenic patients.
    Pristach CA; Smith CM
    Hosp Community Psychiatry; 1990 Dec; 41(12):1345-8. PubMed ID: 1980483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance abuse in clozapine-treated schizophrenic patients.
    Sand PG; Soyka M
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):626-7. PubMed ID: 9447510
    [No Abstract]   [Full Text] [Related]  

  • 18. Predicting medication noncompliance after hospital discharge among patients with schizophrenia.
    Olfson M; Mechanic D; Hansell S; Boyer CA; Walkup J; Weiden PJ
    Psychiatr Serv; 2000 Feb; 51(2):216-22. PubMed ID: 10655006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marijuana use in schizophrenia: a clear hazard.
    Treffert DA
    Am J Psychiatry; 1978 Oct; 135(10):1213-5. PubMed ID: 29496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and therapeutic aspects of agitation].
    San L
    Encephale; 2007 Jun; 33 Pt 3():S375-9. PubMed ID: 19101354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.